Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.
Published Mar 21, 2006 · S. Zoungas, B. McGrath, P. Branley
Journal of the American College of Cardiology
241
Citations
9
Influential Citations
Abstract
Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
Key takeawayHigh-dose folic acid does not slow atheroma progression or improve cardiovascular morbidity or mortality in patients with chronic renal failure.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.